Capreomycin: A Literature Course

Capreomycin is a cyclic peptide antibiotic that has been investigated chiefly as an injectable anti-tuberculosis agent. This course organises the verified published literature into six modules so that readers can see what was measured, in which system, and what researchers reported. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about diagnosis, treatment or medicines. Nothing here is a protocol, a recommendation, or a claim of benefit.

One structural point shapes the whole course: the verified evidence set consists almost entirely of microbiology, molecular genetics, biophysics and analytical chemistry papers. Where a module would normally carry human dosing, exposure or adverse-event numbers, those numbers are absent from this evidence set, and the module says so rather than borrowing figures from elsewhere.

Module 1 — What capreomycin is and how it has been studied

Capreomycin belongs to the tuberactinomycin group of cyclic peptide antibiotics. It is not a metabolic or "wellness" peptide; it is a fermentation-derived antibacterial substance formulated as capreomycin sulfate for parenteral use. The compound is a mixture of closely related congeners rather than a single molecule, which is why analytical characterisation has been a recurring research theme: one chromatographic study isolated and identified four major impurities in capreomycin sulfate using preparative separation and structural elucidation techniques (PMID 30115387).

Its biological origin has also been studied from the producer's side. Researchers examining the capreomycin-producing actinomycete reported a dual mechanism of self-resistance, meaning the organism that makes the antibiotic protects itself through two distinct routes rather than one (PMID 34994196). Work in this area has practical value for understanding where resistance determinants come from and how they might move.

How has capreomycin been studied? In the verified set, the dominant designs were: bacterial susceptibility and combination testing in culture; genetic association of specific mutations with reduced capreomycin activity; multi-omics profiling of resistant or tolerant strains; functional screening for resistance genes; and one protein-biophysics study outside the antibacterial field entirely, in which capreomycin was applied to an amyloid fibrillation model (PMID 29496560).

Limits of the evidence in Module 1

Chemical and genetic characterisation does not describe clinical behaviour. The impurity study described drug-substance composition, not what happened in patients (PMID 30115387). No paper in this set compared different manufactured forms of capreomycin in a living organism, and none established which congener profile matters for any outcome.

Module 2 — Mechanism as described in the literature

Capreomycin is described in this literature as acting on the bacterial ribosome and therefore on protein synthesis, with its activity strongly modulated by ribosomal RNA modification. The clearest genetic evidence comes from work on tlyA: a multi-omics study assessed capreomycin resistance in tlyA-deficient and tlyA point-mutation (G695A) Mycobacterium tuberculosis strains and reported that loss or alteration of this gene was associated with resistance to the drug (PMID 31279617). That result is mechanistically informative because it ties susceptibility to the modification state of the drug's target rather than to drug uptake alone.

Resistance genetics has widened since then. A 2024 study reported that a K114N mutation in rv2820c was related to capreomycin tolerance, identifying a determinant outside the classical target-modification pathway (PMID 39084000). Separately, researchers discovered and characterised genes conferring natural resistance to capreomycin, showing that resistance determinants exist in nature independent of clinical exposure (PMID 38114770). The producer organism's dual self-resistance mechanism sits in the same conceptual space: two parallel protective routes rather than a single modification (PMID 34994196).

A further mechanistic layer is genetic background. A 2025 study reported that different rpoB mutations had diverse impacts on the anti-tuberculosis efficacy of capreomycin, meaning that mutations primarily associated with another drug class did not affect capreomycin activity uniformly (PMID 40449326).

Outside bacteriology, one biophysical study reported that capreomycin inhibited the initiation of amyloid fibrillation and suppressed amyloid-induced cell toxicity in vitro, an activity unrelated to ribosomal inhibition (PMID 29496560).

Limits of the evidence in Module 2

Mechanistic inference here is largely genetic and correlative. Reporting that a mutation is "related with" tolerance describes association within the tested strains (PMID 39084000), and multi-omics profiling generates candidate pathways rather than proof of a single causal step (PMID 31279617). The amyloid finding was a cell-free and cell-culture observation, not evidence of activity in an animal or a person (PMID 29496560).

Module 3 — Reported outcomes by study

The table below maps each verified paper to its system and its reported endpoint. No entry should be read as a promise of benefit; these are laboratory endpoints, and several concern resistance rather than efficacy.

Read together, the pattern is consistent: the recent capreomycin literature in this set is dominated by resistance biology. Two papers from 2025 approached the problem from opposite directions — one asking how host-strain rpoB genotype changed capreomycin efficacy (PMID 40449326), the other asking what else becomes resistant once capreomycin itself has been the selecting agent (PMID 41362315). The single combination study reported in vitro synergy with clofazimine, which is a culture-based interaction measurement rather than a treatment outcome (PMID 31200023).

Limits of the evidence in Module 3

None of these reports was a clinical efficacy trial. In vitro synergy does not establish that a combination performs better in an infected host (PMID 31200023), and susceptibility of an organism in culture does not establish clinical usefulness against that organism (PMID 35958801). Strain collections were geographically and genetically limited, and resistance endpoints were measured under laboratory selection rather than during treatment of patients (PMID 41362315).

Module 4 — Capreomycin Side Effects: What Studies Report

This is the part of the course where the verified evidence set is thinnest, and the honest answer matters more than a long list. None of the ten verified papers was a clinical safety study, a pharmacovigilance analysis or an adverse-event cohort. They therefore report no incidence rates, no organ-toxicity frequencies and no patient-level tolerability data for capreomycin.

The toxicity-adjacent observations that do exist in this set are cellular and chemical:

• Cell-level toxicity endpoints. The amyloid study measured cytotoxicity in cultured cells exposed to amyloid species and reported that capreomycin suppressed amyloid-induced cell toxicity in that system (PMID 29496560). That is an assay of protection against an external insult, not an assessment of the antibiotic's own safety profile.
• Impurity characterisation. Analytical work identified four major impurities in capreomycin sulfate (PMID 30115387). Impurity identification is a quality-control activity that supports safety assessment; the study did not report biological or toxicological consequences for the impurities it described.
• Microbiological testing only. The susceptibility and combination studies measured bacterial growth inhibition in culture and reported no host-side adverse outcomes, because no host was involved (PMID 35958801, PMID 31200023).

Clinical adverse-event information for capreomycin exists, but it lives in approved-product prescribing information and in clinical treatment literature that falls outside this verified set. Because this course cites only verified papers, those figures are not reproduced or paraphrased here. Questions about tolerability in a specific person belong with a licensed clinician who can consult current labelling.

Limits of the evidence in Module 4

Absence of adverse-event reports in a laboratory paper is not evidence of safety. The studies above were not designed to detect harm in a living organism, had no comparator arm and involved no follow-up period (PMID 29496560, PMID 30115387).

Module 5 — Pharmacokinetics where data exist

Within the verified set, no study reported pharmacokinetic parameters for capreomycin: there are no absorption, distribution, metabolism, elimination, half-life, clearance or plasma-concentration data. The designs were not built to produce them. The combination and susceptibility experiments used defined drug concentrations in culture medium rather than exposures achieved in a body (PMID 31200023, PMID 35958801), and the genetic and multi-omics studies described strain responses to drug pressure rather than drug disposition (PMID 41362315).

The closest adjacent information is compositional. Because capreomycin sulfate is a mixture of related cyclic peptides, the identity and proportion of its components and impurities are chemically relevant to any exposure discussion, and researchers characterised four major impurities in the drug substance using chromatographic and structural methods (PMID 30115387). Composition, however, is an input to pharmacokinetics, not a substitute for measuring it.

Limits of the evidence in Module 5

No dose, interval, exposure target or concentration–effect relationship in a living organism can be stated from this evidence set, and none is stated on this page. Any concentration used in the cited in vitro work applied to culture conditions in that experiment only (PMID 31200023).

Module 6 — Regulatory status

Capreomycin is a regulated pharmaceutical, not a research chemical marketed for general use. Capreomycin sulfate has existed as an approved injectable prescription antibiotic for tuberculosis in several jurisdictions, supplied as a sterile powder for reconstitution; approval status, product availability and labelling differ by country and can change over time. International tuberculosis treatment guidance has also shifted over the years in how it positions injectable second-line agents relative to oral regimens, so guideline placement and marketing status are separate questions from whether a product exists.

Alongside approved medicines, capreomycin is also distributed as a research-use-only (RUO) laboratory reagent — for example as an antibiotic standard for susceptibility testing or as a selection agent in microbiology. RUO material is labelled for laboratory investigation and is not intended for human or veterinary administration. Studies of the kind summarised in this course use reagent-grade material under laboratory conditions, and analytical work on capreomycin sulfate composition is part of the quality framework that distinguishes pharmaceutical-grade drug substance from unqualified material (PMID 30115387).

On compounding: in the United States, pharmacy compounding under sections 503A and 503B of the Food, Drug, and Cosmetic Act operates within defined conditions, including requirements about the bulk drug substances that may be used and the circumstances under which a compounded preparation may be prepared. Whether any particular substance may be compounded is determined by those rules and by state pharmacy law, not by a substance's appearance in the research literature. This section describes regulatory categories as published; it is general information and not legal advice.

Limits of the evidence in Module 6

Regulatory categories describe legal handling, not biological effect, and none of the verified papers examined regulatory or prescribing practice. Readers checking current status should consult primary regulatory sources for their jurisdiction, because approval, labelling and guideline recommendations are all subject to revision.

What the studies did not test

Drawing the boundary is the most useful thing a literature course can do. Across the ten verified papers, the following were not tested:

1. Human clinical outcomes. No study in this set reported cure rates, culture conversion, relapse, survival or symptom endpoints in patients.
2. Human safety endpoints. No adverse-event incidence, laboratory-abnormality frequency or organ-toxicity monitoring data appear in these papers (PMID 29496560, PMID 30115387).
3. Pharmacokinetics or dosing. No exposure measurements, no dose comparisons and no duration comparisons in humans or animals were reported in this set (PMID 31200023).
4. Non-infectious indications in vivo. The amyloid observation was confined to fibrillation assays and cultured cells, with no animal or human testing reported (PMID 29496560).
5. Clinical consequences of resistance findings. Mutations and gene discoveries were linked to laboratory resistance or tolerance phenotypes, not to treatment failure in defined patient cohorts (PMID 39084000, PMID 38114770, PMID 40449326).
6. Combination regimens in vivo. The clofazimine interaction was assessed in culture, and the study reported no animal or clinical regimen comparison (PMID 31200023).

What the literature does support is a clear scientific picture of capreomycin as a ribosome-directed cyclic peptide antibiotic whose activity is shaped by target modification, by additional tolerance determinants, and by the genetic background of the strain being treated (PMID 31279617, PMID 40449326). That is a mechanistic story, and it is the story these studies were designed to tell.

References

• Diverse impacts of different rpoB mutations on the anti-tuberculosis efficacy of capreomycin (EBioMedicine, 2025)
• Microevolutionary models and multi-omics analysis uncover the cross-drug resistance characteristics of capreomycin-selected Mycobacterium tuberculosis (Current Research in Microbial Sciences, 2025)
• The rv2820c K114N mutation is related with capreomycin tolerance (Tuberculosis, 2024)
• Discovery and characterization of genes conferring natural resistance to the antituberculosis antibiotic capreomycin (Communications Biology, 2023)
• Dual-Mechanism Confers Self-Resistance to the Antituberculosis Antibiotic Capreomycin (ACS Chemical Biology, 2022)
• Evaluation of Susceptibility of the Human Pathogen Helicobacter pylori to the Antibiotic Capreomycin (The Scientific World Journal, 2022)
• Assessing capreomycin resistance on tlyA deficient and point mutation (G695A) Mycobacterium tuberculosis strains using multi-omics analysis (International Journal of Medical Microbiology, 2019)
• Synergistic activities of clofazimine with moxifloxacin or capreomycin against Mycobacterium tuberculosis in China (International Journal of Antimicrobial Agents, 2019)
• Capreomycin inhibits the initiation of amyloid fibrillation and suppresses amyloid induced cell toxicity (Biochimica et Biophysica Acta. Proteins and Proteomics, 2018)
• Isolation and identification of four major impurities in capreomycin sulfate (Journal of Chromatography A, 2018)